Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Phase II trial of pembrolizumab and cabozantinib in HNSCC

Nabil Saba • 3 Jun 2023
ASCO 2023
Head and Neck Cancer Antibodies Cabozantinib Checkpoint Inhibitors Pembrolizumab

Nabil Saba, MD, FACP, Winship Cancer Institute of Emory University, Atlanta, GA, presents findings from a Phase II trial (NCT03468218) of pembrolizumab and cabozantinib in patients with head and neck squamous cell cancer (HNSCC). HPV-positive and negative patients were enrolled and the treatment combination was well tolerated, where progression-free survival and overall survival were additionally encouraging. Additional questions remain regarding the optimal choice of tyrosine kinase inhibitors. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nabil Saba

3:12
Novel immunotherapy approaches in metastatic head and neck cancer
Nabil Saba • 3 Jun 2023
2:19
Elucidating novel biomarkers for head and neck cancers
Nabil Saba • 3 Jun 2023
4:07
Checkpoint inhibition and predicative biomarkers in nasopharynx cancer
Nabil Saba • 3 Jun 2023
1:03
Head and neck updates at ASCO 2023
Nabil Saba • 3 Jun 2023

Related Videos

1:03
Challenges in implementing liquid biopsies for head and neck cancer
Mouadh Barbirou • 7 Apr 2024
2:43
Molecular profiling of tumor biomarkers in head and neck cancer
Mouadh Barbirou • 7 Apr 2024
1:40
The future of squamous cell carcinoma research at ESMO Asia 2023
Brian Henick • 6 Dec 2023
0:54
The role of immunotherapy in PD-L1 low advanced squamous cell carcinoma
Brian Henick • 6 Dec 2023
The content of VJOncology is intended for healthcare professionals